Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey management ... was the reverse split really worth it? Dumb f***s!
Vote NO to the reverse split!!!
And the date on the page is today!
Page Last Updated: 05/21/2018
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=209328&lpcd=ILX
BioElectronics Receives FDA Pre-Submission Approval for its Relief of Musculoskeletal Pain Market Clearance Application
FREDERICK, MD , May 11, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (BIEL) , www.bielcorp.com is pleased to report on the outcome of its Pre-Submission meeting on May 9th, 2018 with the US Food and Drug Administration (US FDA). The FDA’s Pre-Submission Program is designed to organize and give guidance and feedback on clinical data and what regulatory pathway should be followed to get market clearance. The focus of the May 9 pre-submission meeting was in discussing the FDA’s feedback on the clinical outcomes and statistical techniques used in reporting the back-pain study.
Upon reviewing pre-submission information on the ActiPatch® back-pain study (https://clinicaltrials.gov/ct2/show/NCT03240146), the FDA provided positive feedback on the clinical results, and guidance on a 510(k) submission to obtain expanded market clearance for over-the-counter (OTC) treatment of musculoskeletal pain. This would make ActiPatch available as a drug-free, safe, pain relief option for the 126 million Americans (one in two adults) who are suffering with some form of musculoskeletal pain. While ActiPatch is already FDA cleared for treatment of pain from knee osteoarthritis (25 million) and plantar fasciitis (1 million annually), expanded market clearance would allow additional products for the back (42 million), neck (19 million), hip (9 million), shoulder (11 million), carpal tunnel (12 million) and many other musculoskeletal complaints.
The company was represented by their clinical R&D team comprising: Sree Koneru, Ph.D., VP Product Development, Ian Rawe, Director Clinical Research of BioElectronics (BIEL), Kenneth McLeod, Ph.D. Director of Clinical Science and Engineering Research, State University of New York at Binghamton and Richard Staelin, Ph.D. Professor Duke University. Dr. Koneru, who led the discussion, expressed confidence in the FDA’s constructive feedback. “We are pleased that the FDA viewed our data and statistical methods favorably. They have provided guidance on how to combine the back-pain study results, along with our previously cleared 510(k), into a single 510(k) submission for obtaining expedited expanded market clearance.”, he said.
An additional pre-submission meeting is scheduled with the FDA on May 29th, 2018 to seek expanded indications in a separate application for OTC treatment of pain and edema following surgical procedures for its RecoveryRx® medical device.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com
These idiots are going to ruin the stock.
I'm trying to get Fidelity to remove this from my account but they won't!
They say:
-----------------
Your Nct Group Inc have not yet been declared worthless. A security can be declared legally worthless only in the cases given below:
- The bankruptcy court has declared the company bankrupt under Chapter 7 or 11
- The company has no shareholder equity
----------------
This is unbelievable. How can I prove to Fidelity that the company no longer exists? They said they opened up a case to research this and still came back to me that they could not remove this from my account.
These management idiots will do ANOTHER reverse split to get it over $4!
24,969 shares traded??? Is that all?? Less than $55k??? You've got to be kidding me!
Bye bye $2. What a great job these guys are doing. Hmmm .... I wonder how long it will take to get back to pre reverse split levels? What a great idea THAT was!
Looks like pulse lost again.
Down AGAIN! Rinse and repeat.
Down AGAIN. Shocker.
Yeah sure. And then they will need to do ANOTHER reverse split. Keep giving the stock room to go down big.
Reverse split going well.
Down down down. Day after day after day.
Great job management.
White House may boost recreational marijuana enforcement -spokesman
White House may boost recreational marijuana enforcement -spokesman
BY Reuters
— 7:09 PM ET 02/23/2017
WASHINGTON, Feb 23 (Reuters) - The administration of President Donald Trump may ramp up enforcement of federal laws against recreational marijuana use, a White House spokesman said on Thursday, setting up potential conflicts in states where the drug is legal.
More than two dozen U.S. states have legalized marijuana for either medical or recreational purposes, and the administration of former President Barack Obama mostly looked the other way. But White House spokesman Sean Spicer said the Trump Administration may distinguish between medical and recreational use of the drug.
Spicer's comments came on the same day that a nationwide poll from Quinnipiac University in Hamden, Connecticut, showed 71 percent of registered voters favored allowing states to decide whether marijuana should be legal.
"I do believe you'll see greater enforcement of it," Spicer said at a news conference. "Because again there's a big difference between the medical use ... that's very different than the recreational use, which is something the Department of Justice will be further looking into."
Spicer's comments drew criticism from the country's nascent legalized marijuana industry as it was recovering from a scare after Trump's nomination of former Alabama Senator Jeff Sessions, a long time anti-drug campaigner, as attorney general.
"It would be a mistake for the Department of Justice to overthrow the will of the voters and state governments," Aaron Smith, executive director of the National Cannabis Industry Association, said in a statement.
Seventy-five percent of cannabis stocks in an index followed by Arcview Market Research dropped on Thursday after Spicer's remarks, analyst Michael Arrington said in an email.
A spokesman for Sessions, who was confirmed as attorney general earlier in February, declined to comment on marijuana enforcement on Thursday.
But during his confirmation hearings, Sessions said his job was not to enforce only some laws.
Marijuana remains illegal under federal law, but it has been legalized for recreational use in eight states, including Washington, Colorado and California, as well as the District of Columbia. Last year, legal sales reached $7 billion and generated half a billion dollars in sales taxes.
Among registered voters in the Quinnipiac University survey, just 23 percent said the U.S. government should enforce federal laws against marijuana in states that have legalized it for recreational or medical use, and 71 percent said it should not.
The poll of 1323 registered voters, released on Thursday with a margin of error of plus or minus 2.7 percent, also showed support for marijuana legalization among 59 percent of respondents, with 36 percent opposed. (Reporting by Roberta Rampton in Washington, D.C. and Sharon Bernstein in Sacramento, Calif.; Writing by Sharon Bernstein and Eric Walsh; Editing by Chris Reese and Richard Chang)
How's that reverse split working out? Fantastic!
Search for Actipatch on Google and the first link is Amazon!!!!
One-for-10 reverse stock split
Nov 16 (Reuters) - Genvec Inc ( GNVC)
* Says on Nov. 16, co announced it will implement a one-for-10 reverse stock split of outstanding shares of common stock - SEC filing
* Says trading of co's common stock on Nasdaq Capital Market will begin on a split-adjusted basis at opening of trading on Dec. 1 Source text - http://bit.ly/2fZQPxH
ImmunoCellular Therapeutics Announces One-for-Forty Reverse Stock Split
http://investors.imuc.com/releasedetail.cfm?ReleaseID=999674
LOS ANGELES, Nov. 16, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (NYSE MKT: IMUC) announced that at the Special Meeting of Stockholders held on November 14, 2016, ImmunoCellular's stockholders voted to approve a reverse stock split of the Company's issued and outstanding common stock. Upon effectiveness of the reverse stock split, every forty (40) shares of ImmunoCellular common stock will be converted into one (1) share of common stock. Concurrently, the authorized number of shares of the Company's common stock will be reduced from 249 million to 25 million.
ImmunoCellular Therapeutics Logo. (PRNewsFoto/ImmunoCellular Therapeutics) (PRNewsFoto/IMMUNOCELLULAR THERAPEUTICS)
In addition, the reverse stock split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options or warrants outstanding immediately prior to the effectiveness of the reverse stock split, with corresponding increases in the exercise prices of such stock options and warrants. Concurrently, ImmunoCellular will effect a one-for-forty reverse split of its listed warrants that are trading on the NYSE MKT under the symbol IMUC.WS, such that every forty (40) listed warrants will be combined into a listed warrant to purchase one (1) share of common stock at an exercise price of $7.68 per share.
The reverse stock split is intended to enable ImmunoCellular to regain compliance with the minimum bid price required for continued listing on the NYSE MKT as well as to provide a sufficient level of authorized shares of common stock available for issuance and increase the acceptability of the Company's common stock to investors.
Andrew Gengos, ImmunoCellular's Chief Executive Officer, commented: "The management and Board express our gratitude to our stockholders for voting in favor of the reverse stock split, which we undertook with the goal of strengthening our ability to continue to advance our immune-oncology pipeline and technology toward next value inflection points, including the execution of our phase 3 registration trial for ICT-107."
No fractional shares will be issued in connection with the reverse stock split. A stockholder who otherwise would have been entitled to receive a fractional share of stock as a result of the reverse stock split will instead receive cash in lieu of fractional shares. No fractional listed warrants will be issued in connection with the listed warrant reverse split. All fractional listed warrants will be rounded to the nearest whole listed warrant.
The reverse stock split will affect all stockholders proportionately and will not affect any stockholder's percentage ownership of ImmunoCellular shares (except to the extent that the reverse stock split would result in some of the stockholders receiving cash in lieu of fractional shares).
The Company expects the reverse stock split to become effective at 5:00 p.m. Eastern time on November 18, 2016. When the market opens on November 21, 2016, ImmunoCellular's common stock and listed warrants will begin trading on the NYSE MKT on a split-adjusted basis. There will be no change in the Company's NYSE MKT ticker symbols (IMUC, IMUC.WS) as a result of the reverse stock split. The new CUSIP number that will be applicable to the Company's common stock after the reverse stock split is 452536204. The new CUSIP number that will be applicable to the Company's listed warrants after the reverse stock split is 452536121.
Computershare Trust Company, N.A. is acting as exchange agent and transfer agent for the reverse stock split. Computershare will provide instructions to stockholders regarding the process for exchanging their pre-split stock certificates for post-split stock certificates. Additional information regarding the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission on October 4, 2016.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a patient-specific, dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, has been initiated. ImmunoCellular's pipeline also includes: ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. To learn more about ImmunoCellular, please visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements, including statements regarding ImmunoCellular's intentions and current expectations concerning, among other things, ImmunoCellular's ability to meet and maintain the minimum bid price required for continued listing on the NYSE MKT follow the reverse stock split and any effect of the reverse stock split on future market and stockholder interest in ImmunoCellular and its common stock; timing for enrollment and randomization of patients, the activation of clinical sites, the receipt and announcement of clinical data; the development and commercialization of ICT-107; the development of our preclinical Stem-to-T-cell program and ImmunoCellular's ability to achieve its other clinical, operational and financial goals. Forward-looking statements are not guarantees of future performance and are subject to a number of risks and uncertainties, including ImmunoCellular's ability to comply with the continued listing requirements of and maintain its listing on the NYSE MKT, the availability of resources to continue to develop ImmunoCellular's product candidates, the uncertain timing of completion and success of clinical trials, and the risk that ICT-107 can be further successfully developed or commercialized. Additional risks and uncertainties are described under the heading "Risk Factors" in ImmunoCellular's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as required by law, ImmunoCellular undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com
Logo - http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-announces-one-for-forty-reverse-stock-split-300363861.html
SOURCE ImmunoCellular Therapeutics, Ltd.
News Provided by Acquire Media
Oh lookie. Down again, again. What a shocker. Gotta love reverse splits.
Oh lookie. Down again. Slow bleed back to pre-RS price? So far it's turning out just great.
Oh look. Down again.
New buyer here. Initiated at .025. Boy I hope this wasn't a mistake.
Oh lookie. How about that. Down today.
I just took a look at the company's twitter feed. I don't get their tweets? They don't say anything. They just tweet a bunch of hashtags over and over again? What kind of social media presence is that?
PLEASE VOTE AGAINST IT!
Windtree Therapeutics to Host Conference Call and Webcast on Tuesday, October 25, 2016 to Provide a Business Update
WARRINGTON, Pa., Oct. 20, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will host a conference call and webcast (including a slide presentation) at 8:00 a.m. EDT on Tuesday, October 25, 2016 to provide updates on the AEROSURF® phase 2 clinical program and the lung deposition study in non-human primates.
To participate in the live call and take part in the question and answer session, dial (844) 802-2436 (domestic) or (412) 317-5129 (international). The live webcast, including a slide presentation, can be accessed at http://windtreetx.investorroom.com/events .
A replay of the conference call will be accessible one hour after completion through November 1, 2016 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing conference ID number 10095419. An archive of the webcast can be accessed on the Company's website at http://windtreetx.investorroom.com/events
http://windtreetx.investorroom.com/2016-10-20-Windtree-Therapeutics-to-Host-Conference-Call-and-Webcast-on-Tuesday-October-25-2016-to-Provide-a-Business-Update
Vote against both proposals.
----------------------------
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON NOVEMBER 21, 2016
To the Stockholders of Provectus Biopharmaceuticals, Inc.:
NOTICE IS HEREBY GIVEN that a special meeting of Stockholders (the “Special Meeting”) of Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) will be held on Monday, November 21, 2016 at 4:00 p.m. Eastern Standard Time at the offices of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC, located at 265 Brookview Centre Way, Suite 600, Knoxville, TN 37919. The Special Meeting is being held for the following purposes:
1. To approve and adopt an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of common stock, par value $.001 per share (“common stock”), that we are authorized to issue from 400,000,000 to 1,000,000,000 shares; and
2. To authorize our Board of Directors to amend our Certificate of Incorporation, as amended, to effect a reverse stock split of our common stock at a ratio of between 1-for-10 and 1-for-50, such ratio to be determined by our Board of Directors in its discretion.
Stockholders also may transact any other business that properly comes before the Special Meeting.
OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” PROPOSALS 1 AND 2.
Only stockholders of record as of the close of business on October 17, 2016 will be entitled to notice of and to vote at the Special Meeting and any adjournment thereof.
Important Notice Regarding the Availability of Proxy Materials for the Special Meeting to Be Held on November 21, 2016. This Proxy Statement is available at http://www.pvct.com/annual_reports.html.
dlewisfl: Fool? We shall see.
dlewisfl: Patience, Grasshopper.
The damage of management will be done.
Down we go. What a shock. On our way to .29 again. Nice going management. Gotta love reverse splits, right? So stupid.
Funny. We shall see.
They will take too long to uplist. By the time they do, the stock will be right back down to 29 cents. RS is bad.
Then I guess we can expect the usual class action lawsuits if they announce BK. Boy, I really hope BK is not the pending news. I just recently added more shares. So stupid.
So I'm guessing probably bad news, right? Ugh.
Does anyone know what is going on with this right now?
I don't take investment advice from postings on message boards and I don't reveal my current positions on message boards either.
Like I said. We will see in a year.
Sure. I'm confused. We will see in a year (or sooner).
You don't have to believe me. You will see. I will post again referring to this when we are back down at pennies.
RS a HUGE mistake. The stock will be back under $1 in less than a year. DUMB! RS is always DUMB!